The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology. Three reports in the current issue of the Journal of Huntington's disease explore the potential of neuroimaging, proteomic analysis of brain tissu...
Fuente : http://www.eurekalert.org/pub_releases/2013-05/ip-...
Fuente : http://www.eurekalert.org/pub_releases/2013-05/ip-...